Alexion Pharmaceuticals Inc. and Stealth Biotherapeutics Corp. reached a deal for an option to co-develop and commercialize elamipretide for mitochondrial diseases. Read More
Reata Pharmaceuticals Inc. has agreed to pay former partner Abbvie Inc. $330 million plus royalties to reacquire ex-U.S. development, manufacturing and commercialization rights for the Nrf2 activators bardoxolone methyl and omaveloxolone, as well as other next-generation candidates in the class. Rights to certain Asian markets for bardoxolone remain licensed to Kyowa Kirin Co. Ltd. Read More
With phase III trial enrollment underway and expected to enroll about 120 patients, South San Francisco-based Principia Biopharma Inc. disclosed positive preliminary data from its phase II open-label trial testing the oral Bruton tyrosine kinase inhibitor PRN-1008 against pemphigus vulgaris (PV). Read More
There’s a yin and yang to neoantigens, Alberto Bardelli told the audience at the 2019 annual conference of the European Society of Medical Oncology (ESMO) in Barcelona, Spain, last month. Read More
HONG KONG – Upin & Co. Ltd., a fund and asset management company headquartered in London, plans to invest a total of KRW2 trillion (US$1.7 billion) over three years in the South Korean biopharma industry. The U.K. company will use a European fund and human resources network to organize the K-Bio Medical Development Fund (KBMDF), which will include funds of KRW300 billion for the first round, KRW700 billion for the second, and KRW1 trillion for the third round. Read More
The FDA’s Office of Pediatric Therapeutics will hold a public workshop at the agency’s Silver Springs, Md., campus Nov. 12 to discuss pediatric patient-specific engagement in the development of clinical trial endpoints for rare diseases. Read More
Theratechnologies Inc., of Montreal, said its shares began trading on Nasdaq under the symbol TXTX on Thursday. Shares will continue to be listed on the Toronto Stock Exchange under the symbol TH. Read More
Nicox SA, of Sophia Antipolis, France, which is developing a nitric oxide-donating platform, said it amended its bond financing agreement with Kreos Capital and has drawn down an additional €4 million (US$4.4 million) of debt under the bond financing. Read More
DUBLIN – Shares in Ra Pharmaceuticals Inc. doubled Thursday as UCB SA made a $48-per-share bid that values the company at about $2.5 billion, or about $2.1 billion net of Ra’s cash. Read More
